青青热久久久久综合精品,日韩国产欧美亚洲精品一二三区,亚洲国产欧美日本视频,中文字幕福利在线观看

            全國(guó)- 「切換城市」 培訓(xùn)家旗下培訓(xùn)平臺(tái)
            手機(jī)版
            網(wǎng)站導(dǎo)航

            職稱英語(yǔ)閱讀輔導(dǎo)講義六)

            2020.02.05

            發(fā)布者:網(wǎng)上發(fā)布

              Once-daily Pill Could Simplify HIV Treatment

              Bristol-Myers Myers Squibb and Gilead Sciences have combined many HIV drugs into a single pill Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and HIV/AIDS,2 for example, are all treated with ____1____ of drugs. But that can mean a lot of pills to take. It would be ____2____ if drug companies combined all the medicines into a single pill, taken just once a day.

              Now, two companies say they have done that for people just ____3____ treatment for HIV, the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences. They have ____4____ a single pill that combines three drugs currently on the market.3 Bristol-Myers Squibb sells one of them ____5____ the name of Sustiva.4 Gilead combined the ____6____, Emtriva and Viread, into a single pill in two thousand four.

              Combining drugs involves more than ____7____ issues. It also involves issues of competition ____8____ the drugs are made by different companies. The new once-daily pill is the result of ____9____ is described as the first joint venture agreement of its kind in the treatment of HIV

              In January the New England Journal of Medicine5 published a study of the new pill. Researchers compared its ____10____ to6 that of the widely used combination of Sustiva and Combivir. Combivir ____11____ two drugs, AZT7 and 3TC.8 The researchers say that after one year of treatment, the new pill suppressed HIV levels in more patients and with ____12____ side effects.9 Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline.

              Glaxo Smith Kline reacted ____13____ the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.

              The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries. They plan in the next few months to ask the United States Food and Drug Administration10 to ____14____ the new pill.

              There are limits to who could take it because of the different drugs it contains. For example, ____15____ women are told not to take Sustiva because of the risk of birth disorders.11 Experts say more than forty million people around the world are living with HIV

              1. A) conservation B) cooperation C) combinations D) considerations

              2. A) simpler B) more complex C) more meaningless D) more troublesome

              3. A) starting B) stopping C) ending D) discontinuing

              4. A) analyzed B) examined C) explored D) developed

              5. A) before B) after C) under D) above

              6. A) one B) ones C) other D) others

              7. A) social B) technical C) personal D) historical

              8. A) if B) as if C) though D) as though

              9. A) that B) which C) what D) whatever

              10. A) size B) shape C) appearance D) effectiveness

              11. A) excludes B) contains C) looks like D) tastes of

              12. A) few B) fewer C) many D) more

              13. A) for B) with C) to D) into

              14. A) prove B) disprove C) improve D) approve

              15. A) weak B) strong C) elder D) pregnant

             

            首頁(yè) 1 2 尾頁(yè)

            上一篇:職稱英語(yǔ)復(fù)習(xí)講義(四) 下一篇:職稱英語(yǔ)考試必備基礎(chǔ)語(yǔ)法點(diǎn)2

            熱門發(fā)布

            推薦機(jī)構(gòu)

            熱門課程

            本站展示的所有信息內(nèi)容系由機(jī)構(gòu)或個(gè)人用戶發(fā)布,可能存在發(fā)布者所發(fā)布的信息,并未獲得品牌所有人有效授權(quán)。本平臺(tái)會(huì)加強(qiáng)審核,但無(wú)法完全排除差錯(cuò)或疏漏。鄭重聲明:本平臺(tái)僅為免費(fèi)注冊(cè)用戶提供免費(fèi)的信息發(fā)布渠道,但不對(duì)其發(fā)布信息的真實(shí)性、準(zhǔn)確性和合法性負(fù)責(zé),對(duì)此也不承擔(dān)任何法律責(zé)任。對(duì)于從本網(wǎng)站或本網(wǎng)站的任何有關(guān)服務(wù)所獲得的資訊、內(nèi)容或廣告,您接受或信賴任何信息所產(chǎn)生之風(fēng)險(xiǎn)應(yīng)自行承擔(dān),本網(wǎng)對(duì)任何使用或提供本網(wǎng)站信息的商業(yè)活動(dòng)及其風(fēng)險(xiǎn)不承擔(dān)任何責(zé)任。,如果侵犯,請(qǐng)及時(shí)通知我們,發(fā)送郵件至15610150293@126.com本網(wǎng)站將在第一時(shí)間及時(shí)刪除。